Delving into the Latest Updates on Selinexor with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

CRM1-nuclear-export-inhibitor, NEXPOVIO, Selinexor

+ [13]

Target

ACADS x XPO1

Action

inhibitors

Mechanism

ACADS inhibitors(acyl-CoA dehydrogenase short chain inhibitors), XPO1 inhibitors(Exportin-1 protein inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [9]

Active Indication

Follicular LymphomaRefractory Multiple MyelomaRelapse multiple myeloma+ [66]

Inactive Indication

Acute Myeloid Leukemia with FLT3/ITD MutationAcute Promyelocytic LeukemiaAdenocarcinoma of prostate+ [65]

Originator Organization

Karyopharm Therapeutics, Inc.

Active Organization

Antengene Corp. Ltd.

Sun Yat-Sen University

Karyopharm Therapeutics, Inc.

+ [13]

Inactive Organization

The University of Texas MD Anderson Cancer Center

The University of California, San Francisco

Millennium Pharmaceuticals, Inc.

License Organization

FORUSTherapeutics, Inc.

Antengene Corporation Co., Ltd.

Foundation Medicine, Inc.

+ [12]

Drug Highest PhaseApproved

First Approval Date

United States (03 Jul 2019),

Multiple Myeloma

RegulationPriority Review (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Conditional marketing approval (China), Orphan Drug (South Korea), Orphan Drug (Australia), Priority Review (South Korea), Fast Track (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC17H11F6N7O

InChIKeyDEVSOMFAQLZNKR-RJRFIUFISA-N

CAS Registry1393477-72-9

The primary objective of this Phase Ib/II trial is to study the safety and tolerability of the combination of selinexor, carfilzomib, isatuximab-OBDS** and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma, who have received at least one line of therapy. The phase Ib portion comprises the safety run-in with 6-12 patients, with the option to reduce the selinexor dose from 40 mg to 20 mg if the higher dose reaches the prescribed toxicity threshold. The Phase II portion of the trial will test the Recommended Phase 2 Dose (RP2D) in an expansion cohort of up to 50 patients.

Start Date01 Jul 2026

Sponsor / Collaborator

Hoosier Cancer Research Network

[+3]

NCT07447817

/ Not yet recruitingPhase 2IIT

Investigator-Initiated, Open-Label, Phase II Trial of Selinexor in Combination With Pacritinib in Patients With Myelofibrosis Who Are JAK Inhibitor-Naïve and Have Cytopenias (ILLUMINATE)

This is a phase II, multicenter, open-label trial evaluating the safety and efficacy of pacritinib and selinexor in JAK inhibitor naïve patients with anemia and thrombocytopenia.

Start Date04 May 2026

Sponsor / Collaborator

Icahn School of Medicine at Mount Sinai

[+3]

ChiCTR2600121951

/ Not yet recruitingPhase 2IIT

The Efficacy and Safety of Gecacitinib in Combination with Selinexor Treated intermediate or high-risk Myelofibrosis Patients

Start Date15 Apr 2026

Sponsor / Collaborator-

100 Clinical Results associated with Selinexor

Login to view more data

100 Translational Medicine associated with Selinexor

Login to view more data

100 Patents (Medical) associated with Selinexor

Login to view more data

710

Literatures (Medical) associated with Selinexor

31 Dec 2026·ANNALS OF MEDICINE

Efficacy and safety of Ruxolitinib-based combination therapy in the patients with Myelofibrosis (MF): a systematic review and meta-analysis

Review

Author: Li, Yuxin ; Sun, Wanling ; Cao, Yaofang ; Hui, Wuhan ; Tan, Shuai

BACKGROUND:

Myelofibrosis (MF) is a chronic myeloproliferative neoplasm. Although Ruxolitinib, a JAK1/2 inhibitor, remains the cornerstone of MF treatment, it does not reverse disease progression, and resistance frequently emerges. These limitations have prompted investigation into combination therapies targeting pathways beyond the JAK-STAT axis. This meta-analysis aims to evaluate the efficacy and safety of Ruxolitinib-based combination therapies in patients with MF.

METHODS:

We conducted a systematic search of databases for studies published through August 1, 2025. Thirteen distinct Ruxolitinib-based combination regimens were included. Primary efficacy endpoints were ≥35% spleen volume reduction at 24 weeks (SVR35) and ≥50% reduction in total symptom score (TSS50). Safety endpoints focused on the incidence of grade 3/4 thrombocytopenia and anemia. Subgroup analyses were performed based on prior JAK inhibitor exposure and therapeutic mechanism of action.

RESULTS:

A total of 19 studies comprising 1,088 patients were included in the meta-analysis. Among JAK inhibitor-naïve patients, the combination of Ruxolitinib with Selinexor demonstrated the highest efficacy (SVR35: 92%; TSS50: 78%), followed by Ruxolitinib plus BMS-986158 (SVR35: 90%). For patients with prior JAK inhibitor exposure, Ruxolitinib plus Siremadlin (SVR35: 45%) showed notable activity.

CONCLUSION:

For JAK inhibitor-naïve patients, Ruxolitinib-based combination regimens demonstrated satisfactory clinical responses and the potential for meaningful disease control. For patients with prior JAK inhibitor exposure, the addition of combination therapy drugs may further enhance the efficacy. Personalized treatment selection remains essential, as therapeutic efficacy is significantly influenced by prior JAK inhibitor exposure.

01 Jun 2026·BIOORGANIC CHEMISTRY

PET imaging of XPO1 engagement with [18F]selinexor: A pharmacodynamic theranostic strategy for multiple myeloma

Article

Author: Yan, Junjie ; Pan, Donghui ; Su, Chen ; Wang, Lizhen ; Zhong, Xinlin ; Yang, Min ; Xu, Yuping ; Wang, Xinyu ; Chen, Chongyang

Exportin 1 (XPO1), a nuclear export protein frequently overexpressed in multiple myeloma (MM), represents a validated therapeutic target. However, noninvasive imaging approaches capable of assessing XPO1 engagement and pharmacodynamic modulation during therapy remain limited. Here, we present the radiosynthesis and preclinical evaluation of [¹⁸F]selinexor, an XPO1-targeted positron emission tomography (PET) radiotracer derived from the clinically used drug selinexor via an ¹⁸F/¹⁹F isotope exchange method. This labeling approach preserves the parent drug's molecular structure and pharmacological characteristics, enabling in vivo tracking of selinexor. [¹⁸F]Selinexor was synthesized with a radiochemical yield of 23.9 ± 4.1% and molar activity of 0.41 ± 0.08 GBq/μmol. The tracer exhibited favorable stability, XPO1-specific binding, and tumor retention. PET imaging and pharmacokinetic analysis demonstrated rapid systemic distribution followed by slow elimination, closely consistent with known pharmacokinetics of selinexor. Predominant hepatobiliary clearance and prolonged blood retention supported optimal tumor uptake at delayed imaging time points, with tracer uptake peaking at 3 h post-injection in MM.1S (2.92 ± 0.30% ID/g) and NCI-H929 (2.50 ± 0.18% ID/g) xenografts. Uptake was markedly reduced upon blocking, confirming the tracer's in vivo specificity. During therapeutic intervention, repeated selinexor administration effectively suppressed tumor growth and was accompanied by a progressive reduction in tumor uptake from 3.03 ± 0.25% ID/g (day 0) to 0.93 ± 0.13% ID/g (day 15). Notably, this reduction in uptake occurred independently of changes in tumor volume and correlated with decreased XPO1 expression by immunohistochemistry. Conversely, doxorubicin reduced tumor size without affecting uptake, indicating preserved XPO1-associated signal. Together, these findings demonstrate that [¹⁸F]selinexor PET functions as a noninvasive imaging tool for evaluating the in vivo pharmacokinetics and pharmacodynamic behavior of selinexor, and capturing treatment-induced alterations in XPO1 engagement, although further structural optimization will be required prior to potential translation.

01 Mar 2026·iScience

CCT3-mediated regulation of XPO1/RB1 axis stability promotes cellular senescence and tumor progression in clear cell renal carcinoma

Article

Author: Gu, Junfei ; Zhang, Bowei ; Li, Jiehan ; Liu, Yuepeng ; Xu, Chao ; Zhang, Zeyuan ; Cao, Yilong ; Li, Xiaoling ; Shi, Bei ; Dai, Shengtao ; Sun, Qingyun

Cellular senescence's role in clear cell renal carcinoma (ccRCC) remains unclear. We identify CCT3 as a driver of ccRCC progression by enhancing XPO1 stability via correct folding, confirmed by Co-IP and GST pull-down. This promotes nuclear export of tumor suppressors such as RB1 and p21, suppressing cellular senescence. Indeed, experimental evidence showed significantly reduced senescence-associated β-galactosidase (SA-β-gal) activity and altered expression patterns of senescence markers (e.g., p21, CDK4, and cyclin D) in the presence of increased CCT3. Functionally, CCT3 depletion induced robust G1 phase arrest, promoted cellular senescence, and markedly diminished ccRCC cell proliferation, migration, and invasion in vitro. Crucially, in vivo studies demonstrated that the combined therapeutic intervention of CCT3 knockdown and the XPO1 inhibitor Selinexor significantly suppressed tumor growth in ccRCC xenograft models, validating the therapeutic potential of targeting the CCT3-XPO1 axis. In summary, our findings unveil a novel CCT3-XPO1-RB1 axis that orchestrates ccRCC progression by impairing cellular senescence, offering a promising therapeutic avenue for ccRCC treatment.

319

News (Medical) associated with Selinexor

26 Mar 2026

·www.prnewswire.com

Karyopharm Announces $30 Million Private Placement with RA Capital

March 24, 2026 -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has entered into a securities purchase agreement with RA Capital Management for a private placement that is expected to result in gross proceeds of approximately $30 million before deducting placement agent fees and offering expenses, and an additional approximately $44 million of gross proceeds if the accompanying warrants are exercised in full. In the private placement, the Company agreed to sell 1,030,354 shares of common stock at a price of $6.785 per share, 3,391,164 pre-funded warrants at a price of $6.7849 per pre-funded warrant, and accompanying warrants to purchase 4,421,518 shares of common stock with an exercise price of $10.00 per share. The pre-funded warrants will have an exercise price of $0.0001 per share of common stock, will be immediately exercisable and will not expire. The accompanying warrants will be immediately exercisable and will expire 30 days following the public announcement by the Company of topline results from the Phase 3 XPORT-EC-042 clinical trial of selinexor in patients with endometrial cancer. The private placement is expected to close on or about March 26, 2026, subject to the satisfaction of customary closing conditions. The private placement was priced at-the-market under Nasdaq rules. The Company expects that the net proceeds of the private placement, together with its existing liquidity, including cash, cash equivalents and investments, as well as cash flow from net product revenue and license and other revenue, will enable it to fund its current operating plans into late Q3 2026. The Company intends to use the proceeds from the private placement for general corporate purposes, including to support the Company's ongoing and planned clinical trial activities. Jefferies and Piper Sandler acted as placement agents for the private placement. The offer and sale of the shares of common stock, pre-funded warrants, warrants, or any other securities (including the shares of common stock issuable upon exercise of the pre-funded warrants and warrants) are not being registered under the Securities Act of 1933, as amended (the "Securities Act"), or any state securities laws. The shares of common stock, pre-funded warrants, warrants, or any other securities (including the shares of common stock issuable upon exercise of the pre-funded warrants and warrants) may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and any applicable state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy shares of common stock, pre-funded warrants, warrants, or any other securities, nor shall there be any offer, solicitation or sale of shares of common stock, pre-funded warrants, warrants, or any other securities (including the shares of common stock issuable upon exercise of the pre-funded warrants and warrants) in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful. Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in 50 ex-U.S. territories and countries, including the European Union, the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). The content above comes from the network. if any infringement, please contact us to modify.

Drug Approval

25 Mar 2026

·www.biospace.com

Karyopharm Slides as Mixed Myelofibrosis Results Cloud Regulatory Road

iStock, beast01 Missing one of its co-primary endpoints could make it difficult for Karyopharm Therapeutics to score conventional approval for Xpovio in myelofibrosis, according to Jefferies analysts. Karyopharm Therapeutics’ push to expand its multiple myeloma drug Xpovio into myelofibrosis has hit a speedbump. Tuesday, the biotech unveiled mixed results in a Phase 3 myelofibrosis study, with an investigational Xpovio regimen meeting just one of two primary endpoints. Following the readout, the company’s shares dropped to $5.44 apiece at market close, an 18.3% decrease from its previous closing price. Karyopharm nevertheless intends to engage with the FDA to discuss “the totality of the data” and see how that might shape up to a regulatory path forward for Xpovio in this indication, according to a Tuesday release . Jefferies, however, isn’t optimistic: “We see low chance of conventional FDA approval w/ current dataset,” analysts told investors in a note sent the same day. Xpovio is an oral nuclear export inhibitor that was approved in 2019 in combination with dexamethasone for patients with relapsed or refractory multiple myeloma who have undergone at least four prior lines of therapy. Last year, the drug made $114.9 million . Karyopharm forecasts net U.S. product revenue to be between $115 million to $130 million this year. In the Phase 3 SENTRY study , Karyopharm combined Xpovio with ruxolitinib, a JAK inhibitor that is marketed by Incyte under brand names such as Jakafi and Opzelura. The trial enrolled more than 350 patients with myelofibrosis and who had never been treated with JAK inhibitors. Comparators were given placebo plus ruxolitinib. At 24 weeks, 50% of patients treated with the Xpovio combo achieved at least a 35% decrease in spleen volume, a key disease marker. At the same time point, 28% of comparators on ruxolitinib alone hit this endpoint, resulting in a statistically significant advantage for the Xpovio regimen. Xpovio was able to sustain this benefit over time, with 47% of patients maintaining a 35% spleen volume reduction by 36 weeks, versus 23% in controls. However, the Xpovio regimen failed to hit SENTRY’s other co-primary endpoint of symptom improvement, as measured by a change in the absolute total symptom score. Patients treated with Karopharm’s combo saw a 9.89-point improvement in the scale, versus 10.86 points in those who received ruxolitinib alone. A key opinion leader consulted by RBC Capital Markets “did not seem as concerned about the trial not hitting on its symptom scale endpoint,” the firm told investors in a Tuesday note. The expert, RBC continued, pointed out that ruxolitinib’s symptomatic benefits “are so robust that . . . it may not be possible for any drug to hit on this endpoint.” What interested the expert more were the survival signals that Karyopharm reported. The biotech touted “promising” overall survival (OS) outcomes in its Tuesday release, with the Xpovio- ruxolitinib combo reducing the risk of death from any cause by 57% versus controls. A posthoc analysis also showed that the spleen volume response could be predictive of overall survival. While RBC’s key opinion leader has expressed “some caution” about whether this survival signal is real, he nevertheless “believes this would be a very meaningful finding if it plays out longer-term,” the firm said. A significant survival benefit, analysts added, would trump the symptom score miss. Karyopharm intends to present its OS data to the FDA in building its case for Xpovio’s expansion into myelofibrosis, the biotech said on Tuesday, though it did not yet provide a specific timeline for when such a filing could occur.

Clinical ResultPhase 3Drug Approval

24 Mar 2026

·www.fiercepharma.com

Karyopharm, looking to jump-start Xpovio, reports mixed results in myelofibrosis

Karyopharm has seen sales stagnate for Xpovio. But the Massachusetts company hopes that mixed results can pave the way to FDA approval in a new indication for the nuclear transport modulator. After gaining approval to treat multiple myeloma and generating sales of $120 million in its third full year on the market, Karyopharm’s Xpovio has stagnated in the clinic and in the market.On Tuesday, the Massachusetts company provided results from a phase 3 trial that it hopes can help the nuclear transport modulator regain some of its momentum. But investors aren’t sharing in the company’s enthusiasm, with shares falling sharply after the readout and a separate financial development at the company.Testing Xpovio (selinexor) in combination with Incyte and Novartis’ blockbuster Jakafi (ruxolitinib) in patients with first-line myelofibrosis (MF), the study met one of its two primary endpoints, with the combo demonstrating a statistically significant improvement in spleen volume reduction of 35% or more (SVR35) compared to Jakafi and placebo.The experimental combo produced spleen responses in 50% of patients, compared to a 28% figure for the control arm, Karyopharm said in a press release.The trial did not achieve its co-primary endpoint, however, it came up short on patient-reported symptom scores after 24 weeks compared to baseline. As measured by the Absolute Total System Score (Abb-TSS), patients on the combo reported a 9.9-point improvement, compared to a 10.9 improvement for those on Jakafi and placebo.On a Tuesday morning conference call, Karyopharm CEO Richard Paulson called the data an “important milestone” for the company and “an encouraging step forward” for patients who have MF.“These results suggest the potential to improve on key dimensions of treatment benefit in a disease where patients and physicians continue to need better options,” Paulson said, adding that the company plans to meet with the FDA to discuss the data and a potential submission for approval in the indication. Naturally, Karyopharm focused on the spleen volume aspect of the trial, in which the combo produced rapid and sustained results. After 12 weeks, 49% of patients on the combo achieved SVR35 compared to 20% in the control arm. The durability of the combo was demonstrated at week 36 by 47% of patients achieving the standard compared to 23% of those on Jakafi and placebo.Additionally, the company said the trial results indicated a positive overall survival signal for the combo. Karyopharm added that post-hoc analyses at weeks 12 and 24 suggest SVR35 “may predict overall survival.” The company will continue to monitor patients in the trial to evaluate overall survival.“The early, the sustained, the substantial proportion of patients that achieved that SVR really demonstrates that meaningful benefit, layered on top of the promising overall survival signal and a manageable safety and tolerability profile really suggest a positive benefit,” Reshma Rangwala, M.D., Ph.D., Karyopharm’s chief medical officer, said during the call. “We look forward to engaging with the FDA on the totality of that data.”Separately on Tuesday, Karyopharm revealed a new financing arrangement with RA Capital Management, under which it will generate $30 million in proceeds from the sale of 1.03 million shares of its common stock for $6.79 each. This likely played some role in the company’s share movement Tuesday.Karyopharm has struggled in recent years, with its share price declining more than 95% over the last 5 years. After the twin news releases Tuesday, shares were down some 17%. After gaining three FDA nods in a span of 17 months for Xpovio, the FDA rejected an expansion bid for the drug to be used as a maintenance therapy in endometrial cancer. In each of the last four years, annual sales have been stagnant, toggling between $112 million and $120 million.In 2023, the company executed a round of layoffs, reducing its headcount by 20%. Last year came another 20% reduction. It opened this year with 228 employees, down from 442 at the start of 2022.

Clinical ResultPhase 3License out/in

100 Deals associated with Selinexor

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D11222	Selinexor	L01XX66	DB11942

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Follicular Lymphoma	Indonesia	Antengene Corp. Ltd.	05 Mar 2025
Refractory Multiple Myeloma	China	Karyopharm Therapeutics, Inc.	14 Dec 2021
Relapse multiple myeloma	China	Karyopharm Therapeutics, Inc.	14 Dec 2021
Diffuse large B-cell lymphoma recurrent	Israel	Karyopharm Therapeutics, Inc.	04 Feb 2021
Diffuse large B-cell lymphoma refractory	Israel	Karyopharm Therapeutics, Inc.	04 Feb 2021
Diffuse Large B-Cell Lymphoma	United States	Karyopharm Therapeutics, Inc.	22 Jun 2020
Multiple Myeloma	United States	Karyopharm Therapeutics, Inc.	03 Jul 2019

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Refractory acute myeloid leukemia	Phase 3	China	Antengene Corp. Ltd.	29 Jan 2023
Relapsing acute myeloid leukemia	Phase 3	China	Antengene Corp. Ltd.	29 Jan 2023
Endometrial Carcinoma	Phase 3	China	Antengene Corp. Ltd.	27 Oct 2021
Endometrial Carcinoma	Phase 3	China	Karyopharm Therapeutics, Inc.	27 Oct 2021
Post-polycythemia vera myelofibrosis	Phase 3	United States	Karyopharm Therapeutics, Inc.	11 Mar 2021
Post-polycythemia vera myelofibrosis	Phase 3	Australia	Karyopharm Therapeutics, Inc.	11 Mar 2021
Post-polycythemia vera myelofibrosis	Phase 3	Belgium	Karyopharm Therapeutics, Inc.	11 Mar 2021
Post-polycythemia vera myelofibrosis	Phase 3	Bulgaria	Karyopharm Therapeutics, Inc.	11 Mar 2021
Post-polycythemia vera myelofibrosis	Phase 3	Canada	Karyopharm Therapeutics, Inc.	11 Mar 2021
Post-polycythemia vera myelofibrosis	Phase 3	Czechia	Karyopharm Therapeutics, Inc.	11 Mar 2021

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04925193 (CTgov)	Phase 2	Relapse multiple myeloma	18	Carfilzomib+Daratumumab+Dexamethasone+Selinexor+pomalidomide	ucixhvncjs = ysaptwrvjw nqxmldagur (ihlcsiuacq, jkmufvmcvv - gkifhhckjl) View more	-	06 Mar 2026
NCT04856189 (CTgov)	Phase 1/2	Advanced Urothelial Carcinoma \| Locally Advanced Urothelial Carcinoma \| Metastatic urothelial carcinoma	4	Selinexor+Pembrolizumab	czevfvoftg = augqrbqymx lhdjywdzbv (tkpdyttbkx, phaxyfckrg - abphkgfyzc) View more	-	29 Jan 2026
NCT04595994 (Pubmed \| Nat Commun)	Phase 1	Sarcoma	17	Gemcitabine + Selinexor	vbrsrehzfy(nmdaykqkzi) = gemcitabine at 1200 mg/m2 at 10 mg/m2/min followed by 60 mg weekly selinexor tucvdxutsb (uuwkxpyzmr ) View more	Positive	20 Jan 2026
ASH2025	Not Applicable	Acute Myeloid Leukemia	37	XAB regimen	wkkpzugzoz(izqxwukeyb) = qmwsjcxqpq trhfeztexk (pfshhlxgnt ) View more	Positive	06 Dec 2025
ASH2025	Not Applicable	Acute Myeloid Leukemia	37	XAB regimen	wkkpzugzoz(izqxwukeyb) = gyaomlbzav trhfeztexk (pfshhlxgnt )	Positive	06 Dec 2025
EUCTR2021-006229-23-IT (PTCL S-IDE, ASH2025)	Phase 2	Peripheral T-Cell Lymphoma	29	Selinexor+ifosfamide+ etoposide+dexamethasone	ycpsgenivc(zpobbqtkjg) = jnnundhfkn jyiubhenrt (hvwnepquvs ) View more	Negative	06 Dec 2025
NCT05422066 (SADAL, ASH2025)	Phase 2	Diffuse Large B-Cell Lymphoma First line	44	Selinexor + R-CHOP	sqwnjmhkxe(nsisoseycn) = tsokzfxolh mfjkfvknxm (lekszpuces ) View more	Positive	06 Dec 2025
ChiCTR2200064695 (ASH2025)	Phase 2	Renal Insufficiency First line	63	Selinexor + Pomalidomide + Bortezomib + Dexamethasone	udaktmwzzr(gtskpwdveo) = hvrygbwlmi twxfnetqoo (ihjpeqxono ) View more	Positive	06 Dec 2025
SABLe (ASH2025)	Phase 2	Multiple Myeloma First line	47	Selinexor-dexamethasone with alternating lenalidomide and bortezomib	wanawrxkcs(bkicnzxdin) = upsgfczyvs ukfthmmjno (vromzmmhsx ) View more	Positive	06 Dec 2025
ASH2025	Not Applicable	Diffuse large B-cell lymphoma recurrent	54	Selinexor-based regimens bridging CAR-T cell therapy	jutojymgcg(fqffuafuzr) = Grade 1 occurred in 9 patients (60%) and 28 patients (71.8%), respectively; Grade 2 in 1 patient (6.7%) and 4 patients (10.3%); Only one patient in the selinexor-based regimen group experienced Grade 4 (6.7%) CRS. There is no difference between the selinexor-based group and alternative regimen groups (grade 1-4: 73.3% vs 82.1% p=0.475; grade 3 and 4: 6.7% vs 0%; p=0.278). awhdvyvhup (sgrcyqhhve ) View more	Positive	06 Dec 2025
ASH2025	Not Applicable	Diffuse large B-cell lymphoma recurrent	54	Alternative regimen bridging CAR-T cell therapy		Positive	06 Dec 2025
ASH2025	Phase 1/2	Myelodysplastic Syndromes TP53	39	Selinexor sequential azacytidine (TP53 mutations)	dsehvuwuyc(avwpfqbhgg) = bykdfkzgpc rstaawhuia (hhipkpiqak ) View more	Positive	06 Dec 2025